Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner

Telomir Pharmaceuticals, Inc.

Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.
Also associated with reductions in cellular energy metabolism and viability in the same study.
In prior PC3 xenograft mouse model, Telomir-1 reduced tumor volume as single agent; full reduction with paclitaxel combo without mortality.
Paclitaxel alone achieved full tumor reduction but had high mortality; Telomir-1 combo showed no treatment-related deaths.
Company advancing IND-enabling activities for planned IND submission across oncology and aging-related conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.